Why the study?
Do novel oral anticoagulants and other antithrombotics reduce stroke, embolism, and mortality compared to placebo or each other in patients with non-valvular atrial fibrillation?
Population
79,808 patients with non-valvular atrial fibrillation pooled from 20 randomized controlled trials
Comparison
Oral antithrombotics including ASA, ASA plus… vs Placebo/control or active comparators within the…
Design
Meta-analysis
Key result
Novel oral anticoagulants ranked better than VKA or antiplatelet therapies, with dabigatran 150 mg showing the lowest risk of stroke compared to placebo/control (OR 0.25; 95% CrI 0.15-0.43).
Authors
Loading...
Supports preferring NOACs over VKA or antiplatelets for stroke prevention in non-valvular AF; extends network rankings with placebo comparisons.
Meta-Analysis (n=79,808)
Do novel oral anticoagulants and other antithrombotics reduce stroke, embolism, and mortality compared to placebo or each other in patients with non-valvular atrial fibrillation?
Effect estimate: OR 0.25 (95% CI 0.15-0.43)
In a network meta-analysis, novel oral anticoagulants ranked better than vitamin K antagonists or antiplatelet therapies for the prevention of stroke, systemic embolism, and mortality in non-valvular atrial fibrillation.
Dogliotti et al. (2013) conducted a meta-analysis in non-valvular atrial fibrillation (n=79,808). Novel oral anticoagulants (dabigatran, rivaroxaban, apixaban) vs. ASA, ASA plus clopidogrel, vitamin K antagonists (VKAs), or placebo/control was evaluated on Stroke (OR 0.25, 95% CI 0.15-0.43). Novel oral anticoagulants ranked better than VKA or antiplatelet therapies, with dabigatran 150 mg showing the lowest risk of stroke compared to placebo/control (OR 0.25; 95% CrI 0.15-0.43).